Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells

  • Authors:
    • Risa Shiragami
    • Soichiro Murata
    • Chihiro Kosugi
    • Tohru Tezuka
    • Masato Yamazaki
    • Atsushi Hirano
    • Yukino Yoshimura
    • Masato Suzuki
    • Kiyohiko Shuto
    • Keiji Koda
  • View Affiliations

  • Published online on: June 7, 2013     https://doi.org/10.3892/ijo.2013.1978
  • Pages: 431-438
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Fatty acid synthase is highly expressed in many types of human cancers. Cerulenin, a natural inhibitor of fatty acid synthase, induced apoptosis in the human colon cancer cell lines HCT116 and RKO. Oxaliplatin also induced cell death in these cell lines. Cerulenin treatment was associated with reduced levels of phosphorylated Akt, activation of p38 and induced caspase-3 cleavage and finally caused apoptosis. Oxaliplatin induced activation of the p53-p21 pathway and p38. In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin. In xenotransplanted SCID mice, the cerulenin + oxaliplatin group significantly inhibited tumor progression compared to the control, cerulenin and oxaliplatin groups. Based on these studies, inhibiting fatty acid synthase would be an effective strategy to treat unresectable colorectal cancer tumors in combination with oxaliplatin. Fatty acid synthase inhibitor would be one of the best counterparts of oxaliplatin, which reduces the dose and side-effects of oxaliplatin and would make it possible to endure the chemotherapy over a longer period.
View Figures
View References

Related Articles

Journal Cover

August 2013
Volume 43 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shiragami R, Murata S, Kosugi C, Tezuka T, Yamazaki M, Hirano A, Yoshimura Y, Suzuki M, Shuto K, Koda K, Koda K, et al: Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells. Int J Oncol 43: 431-438, 2013
APA
Shiragami, R., Murata, S., Kosugi, C., Tezuka, T., Yamazaki, M., Hirano, A. ... Koda, K. (2013). Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells. International Journal of Oncology, 43, 431-438. https://doi.org/10.3892/ijo.2013.1978
MLA
Shiragami, R., Murata, S., Kosugi, C., Tezuka, T., Yamazaki, M., Hirano, A., Yoshimura, Y., Suzuki, M., Shuto, K., Koda, K."Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells". International Journal of Oncology 43.2 (2013): 431-438.
Chicago
Shiragami, R., Murata, S., Kosugi, C., Tezuka, T., Yamazaki, M., Hirano, A., Yoshimura, Y., Suzuki, M., Shuto, K., Koda, K."Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells". International Journal of Oncology 43, no. 2 (2013): 431-438. https://doi.org/10.3892/ijo.2013.1978